Boston, MA 08/11/2014 (wallstreetpr) – Ebola Virus has already caused thousands of deaths in all parts of the world, especially in Europe and African countries, but drug makers are yet to find out the vaccine. In amidst of deaths all around the world, reports about GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s new vaccine for Ebola can be a motivating factor for all the countries. According to latest reports, the vaccine will go through a clinical trial very soon.
Damage So Far:
So far this deadly virus has caused around 1000 deaths in West Africa alone. Other countries have also reported victims of Ebola Virus. If the situation continues for some more time, then researchers from all around the world can start feeling the pressure to find out the solution for Ebola Virus.
Due to the failure of all the major countries to find out any proven solution for Ebola, the World Health Organization has decided to declare it an international health emergency. GSK has developed a vaccine that has got excellent results in animals and its first phase in humans is due. As soon as the company gets approval from the U.S. Food and Drug Administration, it will start working on the next phase.
According to a spokeswoman of GlaxoSmithKline plc (ADR) (NYSE:GSK), “We are quite hopeful that the next trial will begin in the later part of this year.” Although U.S. National Institute of Allergy and Infectious Diseases (NIAID) said that the trial will begin by the fourth quarter of 2014. According to reports, even if trial begin in a couple of months’ time, there is no guarantee that Ebola Vaccine will be ready by the end of this year. In any case, scientists will be able to produce a vaccine by the first quarter of next year, provided everything goes according to plans during clinical trials. When reporters asked from a GSK representative about the Ebola Vaccine, “He said, it’s still a long way to go so we can’t commit any date as of now.”
